Physician profile
Maya Poplyansky
NPI 1952896664
$835.68
in general payments reported to CMS, 2019-2025
12 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.64 · 2021: $124 · 2022: $155 · 2024: $205 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $147.14 | 2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $135.42 | 2025 | Xiidra, Miebo, Biotrue |
| Coopervision INC. | $124.15 | 2021 | |
| Abbvie INC. | $123.46 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $78.86 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $64.61 | 2024-2025 | Eysuvis, Tryptyr |
| Sun Pharmaceutical Industries INC. | $54.30 | 2019-2025 | |
| Oyster Point Pharma, INC. | $30.53 | 2022-2025 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $25.00 | 2019 | |
| Allergan, INC. | $18.87 | 2022 | |
| Shire North American Group INC | $18.00 | 2019 | |
| Alimera Sciences, INC. | $15.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Poplyansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.